ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONC Oncimmune Holdings Plc

23.10
-0.40 (-1.70%)
27 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40 -1.70% 23.10 22.00 24.20 - 0.00 16:35:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 3.79M -11.39M -0.1639 -1.43 16.33M
Oncimmune Holdings Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker ONC. The last closing price for Oncimmune was 23.50p. Over the last year, Oncimmune shares have traded in a share price range of 13.00p to 51.00p.

Oncimmune currently has 69,475,000 shares in issue. The market capitalisation of Oncimmune is £16.33 million. Oncimmune has a price to earnings ratio (PE ratio) of -1.43.

Oncimmune Share Discussion Threads

Showing 276 to 293 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
24/11/2023
14:09
In this fascinating interview, CEO Martin Gouldstone of Oncimmune - a global leader in immune biomarkers and immunodiagnostics – takes me through the business' new strategy & considerable market opportunity.
brummy_git
12/10/2023
07:19
Encouraging new developments from IPR rich life science firm Oncimmune.

All the details here.

brummy_git
01/8/2023
14:05
Some investors seem unhappy about management changes and dumping - Thoughts?
pugugly
26/6/2023
09:09
Looks to me that the CEO might have been pushed rather than jumped. It feels like someone took a hard headed look and said we can we save @650k per year with minimal operational impact.

I have sympathy for the CEO but this is a needed and refreshing approach.

w t tutte
04/6/2023
16:31
brummy_git

Positive news?

You must definitely be on the payroll

The news is horrific …

kt_aim
04/6/2023
06:04
Once again they have done a terrible job with the communication to market.

Here are the key points of interest to me and that I was able to extract.

-With closure of the Freenome deal they will be in a net cash position.
-Contracted Order Book at 1st March = Euro 3.5 million
-Post 1st March Known Contracts (Freenome) = Euro 2.3 million (minimum)
-Additional Contracts expected to be signed
-Roche Collaborations moving in a promising direction
-The difference between the Current Order book, given in the Chairmans statement and the 1st March Order book suggests that Euro 2.2 million of revenue has already been booked in the second half.
- significant costs will be removed with sale of CDT Lung, related administration and research & development costs, were £1.23M in the first half.
- Once we get clean accounts, cashflow breakeven for the business would appear to be at about a revenue of £4.00M to £4.25M.

40 fathoms
01/6/2023
09:11
JakAss try living in the real world you muppet.

The question was why do you delete your old posts?.

z1co
31/5/2023
22:57
JakAss,you complete plonker for reference this post stays:

=========================================================================
JakNife 31 May '23 - 22:48 - 271 of 272
0 0 2
What a pile of poo this is

* negligible revenue
* revenue down (not a growth company)
* material P&L losses £4,110 loss cf proforma cash
* negative tangible net assets of £9.7m
* a fat cat CEO that's paying himself an exorbitant amount

By the time that the finals are published cash will be running low again and they'll need to raise funds.

JakNife

z1co
31/5/2023
22:52
Hey JakAss

Never mind about this company why do you delete your old posts you pile of poo ???

z1co
31/5/2023
10:15
I dont know what Trek from LSE smoking but i badly need same ;)


He thought to pump before open so that he can sell to others...




Hi R00st3R,

I think todays interims answer your questions. All good at ONC. Well actually very good!

Should be a cracking day today!

Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment.

Wish I could buy more at this price!

Usual caveats

Trek

eva_1989
31/5/2023
08:33
H1'23 results out today from Oncimmune. All the details here.
brummy_git
22/5/2023
08:26
Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.

All the details here.

brummy_git
28/2/2023
08:13
Agreed, many a slip between the cup and the lip, but an easy buy if they are able to deal with the refinancing.
w t tutte
28/2/2023
01:17
Link to post results interview
40 fathoms
27/2/2023
21:16
These numbers are for the 15 months (changed accounting period) to August last year.

Quite a bit has happened since then, not least of which is a big increase in the revenue at immunoinsights business and a smallish CR. As they said in the release today, their income in the 6 months since Aug 22 is higher than for the 15 months reported. They also say they will be operationally cash profitable for the FY ending Aug 23.

40 fathoms
27/2/2023
08:07
There is no way IPL will pull the plug on a business that is clearly able to repay them, they will ask for a pound of flesh but not pull the plug, after all lending to healthcare startup is their business.
40 fathoms
27/2/2023
07:38
"Business continues to perform in line with previously reported expectations, and the Group is now expecting to be operating cashflow positive in FY2023."
40 fathoms
27/2/2023
07:31
Massive cash burn - But DYOR.
pugugly
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com